



CrossMark

“Balloon pulmonary angioplasty for the treatment of chronic thromboembolic pulmonary hypertension: is Europe behind?” Irene M. Lang and Hiromi Matsubara. *Eur Respir J* 2019; 53: 1900843.

The above-mentioned editorial has been corrected and republished online; the amendments have been discussed in the correspondence articles published in this issue of the *European Respiratory Journal* [1, 2]. The sentence that originally read:

“While there are currently 1.7 surgical pulmonary endarterectomies per million of population performed in Europe annually, compared with 0.9 per million in the USA, only approximately 60 pulmonary endarterectomies are performed annually in Japan, accounting for one procedure per billion population.”

has been corrected to:

“While there are currently 1.7 surgical pulmonary endarterectomies per million of population performed in Europe annually, compared with 0.9 per million in the USA, only approximately 60 pulmonary endarterectomies are performed annually in Japan, accounting for 0.47 procedures per million population.”

The table has also been amended and re-formatted for clarity. The new version is reproduced below.

TABLE 1 European versus Japanese balloon pulmonary angioplasty (BPA)

	French reference centre	Hannover and Bad Nauheim	Japanese multicentre registry
Total patients n	184	56	308
Age years	63±14	65 (55–74)	62±13
Females %	49	61	80
Total procedures performed n	1006	266	1408
Procedures per person	5 (median)	5 (median)	4 (median)

	Baseline	After BPA	Baseline	After BPA	Baseline	After BPA
Patients n	154		56	55	308	196
6MWD m	396±120	441±104	358±108	391±108	318±122	430±109
mPAP mmHg	43.9±9.5	31.6±9.0	40±12	33±11	43.2±11.0	22.5±5.4
P_{aO_2} mmHg	65.0±9.0	73.3±12.0	62.0±9.0	66.0±10.0	Not stated	Not stated
S_{aO_2} %	Not stated	Not stated	93.0±3.0	94.0±3.0	93.3±4.5	94.0±5.2
CO L·min ⁻¹	4.8±1.2	5.6±1.4	4.4±1.1	4.6±1.2	Not stated	Not stated
CI L·min ⁻¹ ·m ⁻²	2.7±0.6	3.1±0.8	2.4±0.6	2.5±0.6	2.6±0.8	2.8±0.6
PVR dyn·s·cm ⁻⁵	604±226	329±177	591±286	440±279	854±450	288±195
Patients on riociguat and/or drugs approved for PAH %	62	Not stated	92	Not stated	72	45
Lung injury (% of sessions)	9.1		9.4		17.8	
30-day mortality %	2.2		1.8		2.6	

Data are presented as mean±SD or median (interquartile range), unless stated otherwise. 6MWD: 6-min walk distance; mPAP: mean pulmonary artery pressure; P_{aO_2} : arterial oxygen tension; S_{aO_2} : arterial oxygen saturation; CO: cardiac output; CI: cardiac index; PVR: pulmonary vascular resistance; PAH: pulmonary arterial hypertension.

References

- 1 Jaïs X, Brenot P, Montani D, *et al.* A roadmap for management of chronic thromboembolic pulmonary hypertension. *Eur Respir J* 2019; 54: 1901295.
- 2 Lang IM, Matsubara H. Balloon pulmonary angioplasty for the treatment of chronic thromboembolic pulmonary hypertension: is Europe behind? *Eur Respir J* 2019; 54: 1901639.